ARYx gastrointestinal, cardiovascular news

ARYx terminated all of its employees, including officers, after FDA delayed to 1Q11 a response to an SPA submitted for naronapride ( ATI-7505). ARYx said it was not able to obtain financing to continue operations beyond 2010 due to the delay. All employees entered into consulting agreements to provide services needed to allow the company to function. Naronapride is a cisapride analog serotonin (5-HT4) receptor agonist that has completed a Phase IIb trial to treat chronic idiopathic constipation. ...